IRCT20180222038824N1 IRCT 2018-06-05 Iran University of Medical Sciences Comparing the Effectiveness and Safety of PDpoetin and cinapoetin in the Remodeling of Anemia in Children with Chronic Renal Failure Comparison of the effectiveness and safety between Alpha chain Erythropoietin and Beta chain Erythropoietin produced by Iran in the Remodeling of Anemia in Children with Chronic kidney disease 2018-02-24 anticipated 40 Complete https://irct.ir/trial/29868 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: efficacy and side effects of these two medication made by Iran has not been compared in children, Randomization description: The patients Randomization is Simple and Unit of randomization is individual and according to table of random number the patients are divided to two groups: 1) Alpha chain Epoietin produced by Pooyesh darou 2) Betha chain Epoietin produced by Cinnagen In these two groups, the drugs are prescribed based on KDIGO36 guideline to maintaine hemoglobin range between 11-12 g/dl. In this study concealment was not carried out. 3 alpha and Betha erythropoietin, Anemia in CKD. Intervention 1: Intervention group 1:The patient with CKD and anemia in children Up to 18 years old, Number: 20 patients, drug: alpha chain Epoietin, Dosage: 100 unit/kg, interval: 1-3 dose per week, duration: 3 months,The route Presciption: SQ, Company: pooyesh darou. Intervention 2: Intervention group 2: Intervention group 1:The patient with CKD and anemia in children Up to 18 years old, Number: 20 patients, drug: Betha chain Epoietin, Dosage: 100 unit/kg, interval: 1-3 dose per week, duration: 3 months,The route Presciption: SQ, Company: CinnaGen. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is there is no further information